Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27375341 | 0.87 | LMNA (0.48) | LMNAALDH1A1TDP1TSHR | |
| SCHEMBL22312 | 0.87 | LMNA (0.52) | LMNAALDH1A1TDP1TSHR | |
| SCHEMBL28652710 | 0.87 | LMNA (0.52) | LMNAALDH1A1TDP1TSHR | |
| Alcohol SCHEMBL27715966 | 0.84 | LMNA (0.46) | LMNAALDH1A1TDP1TSHR | |
| Fluoromethane SCHEMBL27452229 | 0.84 | LMNA (0.46) | LMNAALDH1A1TDP1TSHR | |
| Potassium SCHEMBL8328705 | 0.84 | LMNA (0.50) | LMNAALDH1A1TDP1TSHR | |
| Ammonia Solution, Strong SCHEMBL27791838 | 0.84 | LMNA (0.50) | LMNAALDH1A1TDP1TSHR | |
| Methane SCHEMBL1141018 | 0.84 | LMNA (0.50) | LMNAALDH1A1TDP1TSHR | |
| SCHEMBL8211681 | 0.83 | LMNA (0.52) | LMNAALDH1A1 | |
| Acetic Acid SCHEMBL27278804 | 0.82 | LMNA (0.44) | LMNAALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | TLR3, TLR9, TLR1 | LMNA 4409/4885ALDH1A1 4454/4885TDP1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.